COMP <GO>
ARWR vs ABBV // ENTERPRISE SCALE & MARKET CAP
Arrowhead Pharmaceuticals Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: ARWR 5
— ABBV 10
▲ ENTERPRISE SCALE & MARKET CAP LEADER: ABBV
LAST: $59.90 (-0.98%) • MKT CAP: $8.54B
market-cap
$8.54B
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
market-cap
$513.86B
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ARWR VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ARWR | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 70.20% | -29.20 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 11.10% | 29.00% | -17.90 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 73.8x | 33.3x | +40.50 | ABBV | /valuation <GO> |
| Free Cash Flow Yield | 1.84% | 3.47% | -1.63 | ABBV | /fcf-yield <GO> |
| Operating Margin | 11.90% | 24.60% | -12.70 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -0.20% | 6.90% | -7.10 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 180.00% | 8.60% | +171.40 | ARWR | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 6.60 | 5.33 | +1.27 | ARWR | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | ARWR | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.80% | 7.40% | -0.60 | ARWR | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 40.9 | 72.8 | -31.90 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.96 | 1.15 | -0.19 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 18.0x | 113.1x | -95.10 | ARWR | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $8.54B | $513.86B | -$505.32B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ARWR REV | ABBV REV | ARWR GROSS % | ABBV GROSS % | ARWR FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $829.4M | $61.16B | 44.0% | 70.2% | $156.9M | $17.82B |
| FY 2024 | $3.6M | $56.33B | 44.0% | 70.0% | -$604.3M | $17.83B |
| FY 2023 | $240.7M | $54.32B | 44.0% | 44.0% | -$164.7M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ARWR // BETA 0.96
ABBV // BETA 1.15